Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SLIT for Artemisia Annua Allergic Rhinitis
NCT03990272Phase 3Completed
- Sponsor
- Beijing Tongren Hospital
- Start
- Mar 2017
- Primary completion
- Oct 2017
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in allergic rhinitis (AR) comparing artemisia annua allergen extract drops with Placebo drops (2 arms). Primary endpoint: Combined Scores of Medication and Rhinoconjunctivitis Symptoms. Started Mar 2017; status: completed.
02
Drugs
Artemisia annua pollen allergen sublingual drops
03
Conditions
allergic rhinitis (AR)
Beyond the preview
Go deeper on NCT03990272.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03990272.